Slideshow: Assessing Long COVID Complications, Increased Fracture Risk in Diabetes

Diabetes is currently the eighth leading cause of death and disability in the world, with around 500 million people being impacted by the disease. The prevalence of diabetes is also expected to increase, with some estimates putting the total number of diagnosed cases at 1.31 billion by the year 2050. Because diabetes represents a significant public health concern across the globe, developing strategies to control risk factors is crucial.¹

At the Endocrine Society’s 2024 annual meeting, held June 1 to 4 in Boston, Massachusetts, 4 posters presented at the conference looked deeper into diabetes, examining the impact of long COVID, increased fracture risk, the role of low-density lipoprotein (LDL) cholesterol in diabetes development, and liraglutide’s efficacy in reducing cardiovascular complications.

Click here for more of our coverage from ENDO 2024.

Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.

References

1. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023 Jul 15;402(10397):203-234. doi: 10.1016/S0140-6736(23)01301-6. Epub 2023 Jun 22. Erratum in: Lancet. 2023 Sep 30;402(10408):1132. PMID: 37356446; PMCID: PMC10364581.

2. Alieva A. Post-Covid complications in patients with diabetes mellitus are high during 24 month after acute infection. Presented at: ENDO 2024; June 1-4, 2024; Boston, MA.

3. Marion LA, Fremaint AI, Johannesdottir F, et al. Contributions of Skeletal Microarchitecture and Fall Risk to Fractures in Adults with Long-standing Type 1 Diabetes Mellitus. Presented at: ENDO 2024; June 1-4, 2024; Boston, MA.

4. Thiab G. The Independent Association of Low LDL Cholesterol Levels with Diabetes Development Beyond Statin Influence. Presented at: ENDO 2024; June 1-4, 2024; Boston, MA.

5. Del Rosario MP, Ong-Ramos C. A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients With Type 2 Diabetes. Presented at: ENDO 2024; June 1-4, 2024; Boston, MA.